Neurocrine Biosciences
NBIX
486 hedge funds and large institutions have $9.22B invested in Neurocrine Biosciences in 2023 Q1 according to their latest regulatory filings, with 57 funds opening new positions, 200 increasing their positions, 163 reducing their positions, and 86 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 200 | Existing positions reduced: 163
0.3% more ownership
Funds ownership: 93.7% → 94% (+0.3%)
8% less funds holding
Funds holding: 529 → 486 (-43)
14% less capital invested
Capital invested by funds: $10.7B → $9.22B (-$1.49B)
22% less funds holding in top 10
Funds holding in top 10: 9 → 7 (-2)
34% less first-time investments, than exits
New positions opened: 57 | Existing positions closed: 86
42% less call options, than puts
Call options by funds: $17.5M | Put options by funds: $30.2M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$87.3M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$79.8M |
| 3 |
AC
Armistice Capital
New York
|
+$72M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$38.2M |
| 5 |
Primecap Management
Pasadena,
California
|
+$38.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
-$100M |
| 2 |
Invesco
Atlanta,
Georgia
|
-$88.6M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$82.6M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$78.5M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$43.8M |
NBIX Hedge Fund Activity: Q1 2023 in Review
486 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2023, worth a combined $9.22B — down 14% from $10.7B a quarter earlier.
Sellers outnumbered buyers: 86 funds closed out of NBIX and 57 opened new positions — a net loss of 29 holders — while 163 trimmed existing stakes and 200 added.
The largest buyer was BlackRock, adding an estimated $87.3M. The largest seller was Avidity Partners Management, cutting an estimated $100M.
- 486 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2023, down from 529 in Q4 2022.
- Funds reported $9.22B of Neurocrine Biosciences stock for Q1 2023, down 14% quarter-over-quarter.
- 57 funds opened new Neurocrine Biosciences positions in Q1 2023 and 86 closed out, a net change of -29 holders.
- The largest Neurocrine Biosciences buyer in Q1 2023 was BlackRock, an estimated $87.3M added.
- The largest Neurocrine Biosciences seller in Q1 2023 was Avidity Partners Management, an estimated $100M sold.
Based on aggregated 13F filings for Q1 2023.